HomeCompareWUXIF vs ARCC

WUXIF vs ARCC: Dividend Comparison 2026

WUXIF yields 0.94% · ARCC yields 10.65%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 WUXIF wins by $3.66M in total portfolio value· pulled ahead in Year 4
10 years
WUXIF
WUXIF
● Live price
0.94%
Share price
$13.88
Annual div
$0.13
5Y div CAGR
100%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$3.68M
Annual income
$3,055,751.48
Full WUXIF calculator →
ARCC
Ares Capital Corporation
● Live price
10.65%
Share price
$18.02
Annual div
$1.92
5Y div CAGR
-50%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$24.5K
Annual income
$1.14
Full ARCC calculator →

Portfolio growth — WUXIF vs ARCC

📍 WUXIF pulled ahead of the other in Year 4

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodWUXIFARCC
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, WUXIF + ARCC cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
WUXIF pays
ARCC pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

WUXIF
Annual income on $10K today (after 15% tax)
$79.61/yr
After 10yr DRIP, annual income (after tax)
$2,597,388.76/yr
ARCC
Annual income on $10K today (after 15% tax)
$905.66/yr
After 10yr DRIP, annual income (after tax)
$0.97/yr
At 15% tax rate, WUXIF beats the other by $2,597,387.79/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of WUXIF + ARCC for your $10,000?

WUXIF: 50%ARCC: 50%
100% ARCC50/50100% WUXIF
Portfolio after 10yr
$1.85M
Annual income
$1,527,876.31/yr
Blended yield
82.43%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on ARCC right now

WUXIF
No analyst data
Altman Z
9.8
Piotroski
7/9
ARCC
Analyst Ratings
24
Buy
7
Hold
Consensus: Buy
Price Target
$21.88
+21.4% upside vs current
Range: $21.00 — $23.00
Altman Z
0.8
Piotroski
4/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

WUXIF buys
0
ARCC buys
0
No recent congressional trades found for WUXIF or ARCC in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricWUXIFARCC
Forward yield0.94%10.65%
Annual dividend / share$0.13$1.92
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR100%-50%
Portfolio after 10y$3.68M$24.5K
Annual income after 10y$3,055,751.48$1.14
Total dividends collected$3.61M$1.1K
Payment frequencyquarterlyquarterly
SectorStockBDC

Year-by-year: WUXIF vs ARCC ($10,000, DRIP)

YearWUXIF PortfolioWUXIF Income/yrARCC PortfolioARCC Income/yrGap
1$10,887$187.32$11,373$532.74$486.00ARCC
2$12,031$381.20$12,608$279.46$577.00ARCC
3$13,660$787.34$13,809$142.90$149.00ARCC
4← crossover$16,287$1,671.00$15,042$72.20+$1.2KWUXIF
5$21,152$3,724.08$16,341$36.27+$4.8KWUXIF
6$31,672$9,039.75$17,732$18.18+$13.9KWUXIF
7$59,190$25,300.84$19,231$9.10+$40.0KWUXIF
8$151,713$88,379.99$20,851$4.55+$130.9KWUXIF
9$585,758$423,425.00$22,605$2.28+$563.2KWUXIF
10$3,682,512$3,055,751.48$24,504$1.14+$3.66MWUXIF

WUXIF vs ARCC: Complete Analysis 2026

WUXIFStock

WuXi AppTec Co., Ltd., an investment holding company, provides research, development, and manufacturing services to discover, develop, and manufacture small molecule drugs, and cell and gene therapies in the People's Republic of China, rest of Asia, the United States, Europe, and internationally. The company operates through six segments: WuXi Chemistry, WuXi Testing, WuXi Biology, WuXi ATU, WuXi DDSU, and Others. It offers contract research, development, and manufacturing organization services for new drug development from discovery to commercial covering various categories for various synthetic molecular modalities, including small molecules, oligonucleotides, peptides, and complex conjugates; and biology services and solutions that support stand-alone and integrated projects from target discovery to candidate selection and into the clinic. The company also provides seamless drug and medical device testing services from preclinical testing to clinical trials; an integrated end-to-end solution to accelerate time to market for cell and gene therapies; drug discovery services to pharmaceutical and biotech customers; and clinical research services. WuXi AppTec Co., Ltd. was founded in 2000 and is headquartered in Shanghai, the People's Republic of China.

Full WUXIF Calculator →

ARCCBDC

Ares Capital Corporation is a business development company specializing in acquisition, recapitalization, mezzanine debt, restructurings, rescue financing, and leveraged buyout transactions of middle market companies. It also makes growth capital and general refinancing. It prefers to make investments in companies engaged in the basic and growth manufacturing, business services, consumer products, health care products and services, and information technology service sectors. The fund will also consider investments in industries such as restaurants, retail, oil and gas, and technology sectors. It focuses on investments in Northeast, Mid-Atlantic, Southeast and Southwest regions from its New York office, the Midwest region, from the Chicago office, and the Western region from the Los Angeles office. The fund typically invests between $20 million and $200 million and a maximum of $400 million in companies with an EBITDA between $10 million and $250 million. It makes debt investments between $10 million and $100 million The fund invests through revolvers, first lien loans, warrants, unitranche structures, second lien loans, mezzanine debt, private high yield, junior capital, subordinated debt, and non-control preferred and common equity. The fund also selectively considers third-party-led senior and subordinated debt financings and opportunistically considers the purchase of stressed and discounted debt positions. The fund prefers to be an agent and/or lead the transactions in which it invests. The fund also seeks board representation in its portfolio companies.

Full ARCC Calculator →
📬

Get this WUXIF vs ARCC comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

WUXIF vs SCHDWUXIF vs JEPIWUXIF vs OWUXIF vs KOWUXIF vs MAINWUXIF vs HTGCWUXIF vs GBDCWUXIF vs ORCC

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.